Mahtta Dhruv, Elgendy Islam Y, Bavry Anthony A
Department of Medicine, University of Florida, Gainesville, FL, USA.
Division of Cardiology, Department of Medicine, University of Florida, Gainesville, FL, USA.
Cardiol Ther. 2017 Dec;6(2):183-192. doi: 10.1007/s40119-017-0100-z. Epub 2017 Oct 27.
Transcatheter aortic valve replacement (TAVR) has become standard therapy for patients with severe aortic stenosis who are deemed at least intermediate risk for surgical valve replacement. Over the past decade, several technological advances have taken place to improve the quality and safety of these devices. The current commercially available valves are broadly grouped into balloon expandable and self-expandable valves. The latest iteration of the self-expandable valve is Medtronic's repositionable valve known as the Evolut PRO system. In this review, we highlight the evidence behind the use of TAVR, improvement in devices over previous generations, clinical evidence behind the CoreValve Evolut PRO system, and the future of TAVR.
经导管主动脉瓣置换术（TAVR）已成为被认为外科瓣膜置换术至少具有中度风险的重度主动脉瓣狭窄患者的标准治疗方法。在过去十年中，为提高这些设备的质量和安全性已经取得了多项技术进步。目前市面上可买到的瓣膜大致分为球囊扩张式瓣膜和自膨胀式瓣膜。自膨胀式瓣膜的最新版本是美敦力公司的可重新定位瓣膜，即Evolut PRO系统。在本综述中，我们重点介绍了使用TAVR的依据、与前代产品相比设备的改进、CoreValve Evolut PRO系统的临床依据以及TAVR的未来发展。
